Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2012. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share acquisition details related to dividend reinvestment.
- Transaction Price: 1470 pence per Ordinary Share and $46.27 per American Depositary Share (ADS).
- Dividend Date: July 5, 2012.
Material Changes
The filing details specific increases in shareholdings for three individuals following the reinvestment of dividends paid on July 5, 2012. There are no reported material changes to the company's financial position or operations in this document.
- Mrs. D P Connelly: Acquired 24.671 ADSs (personal contribution) and 24.684 ADSs (company matching contribution).
- Mr. M Dunoyer: Acquired 24.760 Ordinary Shares (personal contribution) and 34.393 Ordinary Shares (company matching contribution).
- Mr. W C Louv: Acquired 26.147 ADSs (personal contribution) and 26.175 ADSs (company matching contribution).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document notes that the individuals participated in the plan regarding their 2010 and 2011 bonuses on a post-tax basis. Notional dividends accrued under the matching element will be paid out based on vesting percentages after a three-year measurement period.
Investor Verification Points
- Verify the total number of shares/ADSs held by the named individuals post-transaction to assess insider ownership concentration.
- Confirm the vesting schedule and conditions for the deferred bonus awards mentioned for the 2010 and 2011 periods.
- Review the company's broader financial reports (e.g., Form 20-F) for actual revenue and profit metrics, as this filing contains none.